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ABSTRACT 
 
 
A literature study was conducted to review peptide adhesion to carbon nanotubes and they were 
found to be important in the drug designing industries. To attain target specificity CNTs 
(functionalized with DNA, peptides etc.) have been used as potential vector system. Prior studies 
show that single walled nanotubes (SWNTs) when functionalized with peptides have been 
proven to be better delivery systems than the previous vector delivery systems. Functionalized 
SWNTs can deliver the peptides to the specific target organs in the right concentration without 
having prominent toxic effect. Toxicity studies show that since the SWNTs have shorter half life 
periods most of them get washed away after they deliver the ligands to the target organs. It has 
been shown that SWNTs that are toxic to the body are so solely due to manufacturing defects. 
Pure SWNTs are not toxic to the body. Recently functionalized CNTs are also used for cancer 
therapy.  
A docking study was carried out on interaction of hydrogen and nitrogen functionalized SWNTs 
with peptides where vasopressin is the model peptide. In order to study the effect of dimensions 
of SWNTs and functionalized group attached to the SWNTs on the strength of a bond, binding 
free energies were calculated from the docking models. Hydrogen functionalized, nitrogen 
functionalized and non-functionalized SWNTs binding energies were compared with each other. 
Results show that functionalized SWNTs tend to bind with more peptide molecules than non-
functionalized SWNTs. The interactions on the inner walls of SWNTs are more unstable than the 
outer wall interactions.  
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Chapter 1 
 
Introduction 
 
Since before the dawn of this century, there has been increasing use of the word ‘nano’ in 
the field of biology. ‘Nano’ science is defined as the branch of science that utilizes small 
particles in the nano scale range (10-9 m). These extremely small particles exhibit 
different kinds of mechanical, electronic and structural properties than their macroscopic 
counterparts. For example, a bulk material consists of constant physical properties 
independent of its size. On a small scale, these properties will change with the number of 
atoms on its surface. Therefore, nanoparticles may have different properties from their 
parent bulk materials. Since nanoparticles tend to aggregate, sustaining some of their 
properties may be difficult. With this aggregation, some of the nanoscale properties may 
disappear. Here lies the biggest challenge in the field of nano-science. Recently, proper 
surface engineering techniques have been applied to introduce some kind of repulsive 
forces between nano surfaces such as electrostatic and steric methods (Fig 1), which help 
to prevent aggregation of the particles and retain desirable properties.  In particular, 
carbon nanotubes (CNTs) show promising applications in the biological sciences and 
especially in the medical field [1, 2, 3]. 
2 
 
  
Figure 1: Stabilization of Nano Particles by Means of Electrostatic & Steric Methods.  
 
In the field of drug designing and delivery, one of the major issues has been the 
degradation of the drug before it reaches the target tissue. In order to address this issue, 
active research is being carried out on improving the vector system used for drug 
delivery. Recently carbon nanotubes have been identified as a potential vector system 
when functionalized with peptides, DNA or antigen. The first part of this Thesis involved 
a thorough review on the applications and background study on the use of nanotubes in 
the therapeutic field and proposes future research as a vector for drug delivery. In the 
second part of this Thesis, a docking study was done to calculate the binding free 
energies of interaction of functionalized single-walled carbon nanotubes with a model 
peptide, vasopressin. 
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Chapter 2 
Background Study 
 
2.1 Background on Carbon Nanotube 
 
CNTs are allotropes of carbon. There are mainly two types: a) the single-walled 
nanotubes (SWNTs) and b) the multi-walled carbon nanotubes (MWNTs). SWNTs are 
made of one layer of graphite, which is otherwise known as the graphene sheet made into 
a cylindrical structure. The length to diameter ratio of the structure can exceed 10,000 
making it a nanostructure. MWNTs have a central tubule surrounded by multiple layers 
of graphite spaced by a distance of about 0.34 nm (Fig 2). The diameter range for SWNT 
varies from 0.4 to 2 nm whereas for MWNTs the diameter varies from 1.4 to 100 nm. 
Generally, the SWNTs are found in clusters due to the strong Van der Waals interactions 
resulting in an entangled rope like structure [2]. The chemical bonds in nanotubes are 
primarily sp2-hybridized which are stronger than the sp3-bonds of diamond thus 
contributing to its unique level of strength. 
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Figure 2: Molecular structure of CNT fragments: (left SWNT and right MWNT. The 
distance between the MWNT graphene layers is 0.34 nm). [2] (Reprinted with permission 
from [2] Pastorin, G., Kostarelos, K., Prato, M., and Bianco, A., "Functionalized Carbon 
Nanotubes: Towards the Delivery of Therapeutic Molecules," J. Biomed. Nanotech, 1, 
(2005)133-142. Copyright©American Scientific Publishers, www.aspbs.com.) 
  
SWNTs tend to arrange themselves hexagonally to form a crystal-like structure. These 
unique structures provide their amazing properties. SWNT have greater mechanical 
strengths than iron as well as lower density than aluminum. They are thermally stable up 
to 1400 oC in vacuum. When subjected to a low electric field, they emit electrons making 
them suitable for flat panel display applications. The nanometer scale spaces allow 
adsorption of large amount of gases, like hydrogen. This property of SWNT has been 
utilized in energy storage applications such as fuel cells [4]. Different types of SWNTs 
are shown in Figure 3. 
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Figure. 3: Formation of SWNT [5] and different types of SWNT [4].  
MWNTs, on the other hand, consist of concentric cylinders with each tube having 
different chirality. Transmission Electron Microscopy (TEM) images clearly show 
different distinct layers in the constructions of MWNTs. There are mainly 3 layers of 
graphene layers used in the manufacturing of MWNTs. They are parallel, perpendicular 
and herringbone type (Fig 4) [6].  
 
 
Figure 4: Multiwalled carbon nanotubes [6, 7].  
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2.2 Properties of Carbon Nanotubes 
 
 The SWNT cylinder (Fig 3) can be considered as a molecular scale wire having some 
property-defining parameters as well. The graphene sheets are folded in such a way that 
the beginning and end of a (m, n) lattice vector situated in the graphene plane meet each 
other. This is the simplistic way for the formation of a (m, n) nanotube. The (m, n) 
coordinates are important as they decide the diameter of the nanotube as well as the 
“chirality” of the same [8]. The schematic honeycomb structure of a graphene sheet with 
several lattice vectors has been shown below in Figure 5. 
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Figure 5: Schematic Structure of a Graphene Sheet & SWNTs [8].  
Figure 5a, 5b, 5c and 5d are different SWNTs. Figure 5a is an “Arm-Chair” SWNT as it 
has atoms arranged around the circumference in an arm-chair pattern. For them, m= n. 
Figure 5b, 5c and 5d are “zigzag” SWNTs. They have either m or n equal to zero. The 
angle between base vectors a1 and a2 is termed as θ. For armchair and zigzag structures, θ 
is 30o and 0o respectively. For a (m, n) nanotube, if m – n = 3 x Integer, then the nanotube 
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will possess semiconductor properties, if not, it will have metallic properties. The lattice 
vector v which maps an atom from the left-hand border onto an atom on the right border 
line cannot be arbitrary but is an integer multiple of the two graphite basis vectors “a1” 
and “a2”, i.e. v = na1 + ma2. Here the a1 and a2 vectors are multiplied to increase the size 
of the nanotube. In terms of mechanical strength, they are the strongest and most resilient 
materials to exist in nature and have a Young’s Modulus of 1.2 TPa and tensile strength 
one hundred times more than that of stainless steel, capable of tolerating larger strains 
before failure. In addition, they can exhibit metallic conductivity, chemical and thermal 
stability and elasticity. The tubes attain their tensile property from the covalent sp2 bonds 
that make them stronger than metallic steel. The elastic properties of the nanotubes 
results in having a permanent deformation occurring under excessive tensile stress. The 
electrical property is due to the symmetrical structure of the CNTs and the unique 
electronic structure of the graphene. SWNTs also possess some thermoelectric powers 
(TEP) at high temperature. One of the disadvantages of nanotubes is their inability to 
dissolve in aqueous solution. To remedy this problem, nanotubes can be functionalized 
using hydrophilic groups [8, 9].  
2.3 Surface Functionalization of Carbon Nanotubes 
 
Since carbon nanotubes are insoluble in any kind of solvents, they can be processed only 
in suspended forms. Solubility is an important property where material processing and 
purification are concerned. Functionalization helps in purifying nanotubes from 
carbonaceous materials, reduces the width of tube diameter dispersion and enhances the 
reactivity of the nanotubes. This reactivity enhancement is done mostly with the help of 
nanotubes with smaller diameters. In spite of their instability because of higher curvature 
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energy, smaller diameter tubes show higher reactivity as well as increased deviation from 
the planar (theoretical) graphene properties. Spectroscopic analysis shows [10] that the 
smaller diameter tubes follows deviation from the normal graphene geometry. The 
advantageous part is that from this deviation we can be conversant with the working 
conditions of the nanotubes for specific applications [10]. Figure 6 shows how different 
or deviated the actual grapheme properties are from the theoretical behavior of the 
graphene properties. 
 
Figure 6: Difference between Inverse Tube Diameters Calculated from Density 
Functional Theory (DFT) & Zone Folding for Small Tubes Vs Inverse Zone Folding 
Diameters [10].  
Carbon nanotubes that have been surface modified with some other atoms or groups or 
radicals are often called functionalized CNTs. For example, for bulk processing of CNTs, 
many liquid-phase oxidizing agents have been utilized including nitric acid, sulfuric acid, 
peroxides and potassium permanganate to introduce hydrogen-containing moieties 
associated with the –C-O-, -C=O and –COO- functional groups. In contrast, gas-phase 
functionalization offers the potential for controlled nano-scale functionalization without 
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the generation of liquid waste, as recently demonstrated using photo-oxidation of both 
MWNTs [11, 12, 13] and SWNTs [14]. A wide range of other potential functional groups 
may be used to surface modify CNTs with gas-phase techniques. Recent experiments also 
show [15] affinity of carbon nanotubes towards biological molecules, e.g. antibodies, 
vaccines, drugs, etc.                     
There are mainly two types of functionalization of CNTs: non-covalent and covalent 
functionalization [2]. Non-covalent bonding involves more dispersed variations of 
electromagnetic interactions between the group and the nanotube surface, e.g., 
functionalization of nanotubes with α-Helical amphipatic peptide to bring CNTs into 
solution. Covalent functionalization is sharing of electrons with the surface of the 
nanotubes [2]. There is a wide range of functionalization techniques being used for 
CNTs. A few are briefly discussed below. 
2.3.1 Highly Reactive SWNT Functionalized by Alkyl Halides 
 
Functionalization depends heavily on surface engineering techniques, such as chemical 
vapor deposition. The alkyl halides, trifluoromethane (TFM) and trichloromethane 
(TCM) are often used as functionalization agents [16]. Double bond containing alkyl 
halides, like tetrachloroethylene (TCE) or hexafluoropropene, that form radicals easily, 
are also used as agents [16]. The method is carried out at mild conditions (e.g. at room 
temperature) with the ball milling operations of nanotubes [16]. This process creates 
active sites on the nanotubes by the cleavage of C-C bonds resulting in enhanced 
reactivity as other molecules in gas phase get adsorbed on the nanotube surface [16]. 
Figure 7(a) shows the Transmission Electron Microscopic (TEM) images of non-
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functionalized SWNTs and Figure 7(b) shows after 30 mins of vacuum milling of SWNT 
with TCE.   
 
Figure 7: TEM images of a) Pristine b) for 30 min vacuum-milled SWNT sample [16].  
2.3.2 Highly Reactive & Stable CNT Functionalized by Strong Acids 
 
Chemical functionalization using strong acids is a popular method [17]. The same 
method can be applied to carbon nanotubes in order to increase their reactivity as well as 
dispersion. The three most common acids used to functionalize CNTs are sulfuric acid 
(H2SO4), nitric acid (HNO3) and hydrochloric acid (HCl) are used in different 
combinations to functionalize CNTs. At the very beginning, pristine CNTs are 
synthesized by catalytic vapor deposition techniques with Mo/Fe as catalysts [17]. In the 
next step, they are washed with hydrochloric acid in air to remove all metallic catalysts 
from their surfaces [17]. Three different functionalization techniques have been used 
[17]. In the first one, CNTs are immersed in a mixture of H2SO4/HNO3 (3:1) at room 
temperature. They are then kept in an ultrasound bath for 2-15 hours. Hydrochloric acid 
is then slowly added to the mixture and neutralized subsequently using ammonium 
hydroxide (NH4OH). The entire solution is then filtered with a 0.22 µm cellulose acetate 
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membrane. Nanotubes are washed properly until they reach a pH level of 5.5. For the 
other two functionalization techniques most of the procedures are followed except the 
composition of acids. In the second method [17], hydrochloric acid (HCl) is not used and 
for the third one [17], only nitric acid is used. All of these techniques share a common 
feature that certain percentages of functional groups have been formed on the nanotubes. 
This results in increased reactivity as well as improved dispersion. The first 
functionalization technique using all of the three acids is the most efficient one followed 
by the technique eliminating hydrochloric acid [17]. Dispersion analysis shows that 
suspension stability of CNTs is poor because of the agglomeration of the nanotubes [17]. 
Lack of hydrogen bonding also supports this fact. CNTs functionalized by all of the three 
kinds of acids show the highest stability due to the higher percentage of functional groups 
[17]. Figure 8 shows the TEM images of non-functionalized SWNTs on the left (a) and 
functionalized CNTs on the right (b).  
 
Figure 8: TEM images of a) Pristine & b) Functionalized CNTs [17].  
2.3.3 Bioactive or Natural Species Functionalization 
 
Recently, a new area of application in biological systems has emerged which is known as 
the functionalization with bioactive or natural species [18]. This method primarily 
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involves attachment of biomolecules like proteins, peptides, DNA or antibodies etc. 
Nanotubes not only have a property of attaching biological materials on their surface but 
their cylindrical nature also facilitates the incorporation of peptides or small drugs inside 
their hollow structures. The nanotubes also have the property of attaching peptides on 
their surfaces as well as within their tubular space (Fig 9) to make themselves 
biocompatible [18]. 
 
Figure 9: Molecules inserted within the tubular space of carbon nanotubes [19] 
Recent findings show that single stranded DNA can also be used for functionalization of 
nanotubes which helped to discriminate between metallic and semi-conducting tubes as 
well as in diameter-based identification of the CNTs [18].   
A wide range of proteins or peptides is known to bind to carbon nanotubes either by 
specific or non-specific binding [20]. Sometimes a lot of proteins that are not the subject 
of study tend to bind to the carbon nanotube surface leading to non-specific binding [20]. 
On the other hand, when a protein, which is the subject of study, binds to the surface it is 
called specific binding. The proteins can be inserted in the hollow space in a very 
complicated manner, making it more difficult than just a hydrophobic interaction. 
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Secondary and tertiary structures can affect the non-specific bindings [20]. Recently, this 
non-specific binding issue has been resolved by modifying the nanotubes with mucin 
mimics which make them water soluble while and at the same time inhibiting non-
specific bindings [21]. 
2.3.4 Sidewall Functionalization of SWCNTs 
 
Carbon nanotubes are widely used in biomedical applications because of their cylindrical 
or spherical morphologies, which are stable in hostile environments [22]. Surface 
functionalization makes them biocompatible, enhances their solubility in physiological 
solutions and helps them become more target specific [22]. Still, there are some 
challenges in the world of nanotubes, such as poor reactivity because of lower curvature 
of nanotube walls as well as growing strains in the tubular structures. Hence, there are 
real needs for functionalizing the nanotube sidewalls. One popular method is to attach the 
fluorine groups through direct fluorination [22]. Hydrofluoric acid (HF) is used as a 
reactant [22]. The main goal is to achieve a final stoichiometry of C2F without creating 
any destruction of the tubes. Hence, some process parameters like reaction temperatures, 
reaction times, and catalyst addition are properly controlled. Functionalized nanotubes 
produced by this method are especially applicable for biomedical application as they 
acquire some advantages [22]. For example, the final derivatives are soluble in different 
polar solvents as well as in alcohols. Not only that, Transmission Electron Microscopy 
(TEM) shows the diameter of the fluorinated or functionalized nanotubes to be less than 
(almost 1/10th) than that of the parent nanotubes. The results prove their good dispersion 
and easy processibility and make them suitable for biomedical application [22].  Figure 
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10 shows the reaction when amino derivitized SWNTs (Fig 10(1)) were reacted with 
adiphyl chloride creating amide linkages. The resulting polymer 2 (Fig 10(2)) is formed 
as a result of a cross-linked condensation reaction.  
 
 
  Figure 10: Typical Sidewall Reaction-Amino SWNT Derivatives (1) React with 
Adiphyl Chloride [22].  
Figure 11 shows the microscopic images of Fluoro-SWNTs on the left (Fig 11A) and 
polymer 2 on the right (Fig 10B). 
 
Figure 11: SEM images of F-SWNTs (A) & Nylon-SWNT Polymer 2(B) [22].  
2.4 Drug Delivery Vectors  
 
In the field of drug discovery and delivery, drug-delivery vectors play a very important 
role. The vectors are used to carry the drug to the target organs. Generally, almost half of 
the potential drug candidates, selected by high throughput screening, are rejected and 
never reach the step of final formulation, mainly due to their poor water solubility [23]. 
For an efficient drug delivery system, it is also important to deliver the drug to its target 
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region in the right concentration. In order to design an efficient vector, a balance between 
hydrophobic and hydrophilic properties is desired. Drug delivery systems (DDS) are 
designed to improve the pharmacological profile of a drug, to alter the pharmacokinetics 
(PK) and bio-distribution (BD) of a molecule, or to act as drug reservoir. Of the different 
types of DDS, liposomes are one of the most efficient systems [24]. A liposome is a 
spherical vesicle with a membrane composed of a phospholipids and cholesterol bilayer 
(Fig 12). 
 
                                    Figure. 12: Liposomes used for drug delivery [25] 
Liposomes were described as drug delivery vehicles in the 70s, on the basis of their 
ability to increase the efficacy of the drug with reduced toxic side effects [24]. Some of 
the major disadvantages of liposomes are still unresolved, such as a limited physical 
stability of the dispersions, non-specific clearance by the mononuclear phagocytic 
systems (MPS) and a difficulty in up scaling production of some advanced liposome 
types [24]. MPS systems detect the liposomes as foreign bodies and so the liposomes are 
cleared by the body’s immune system. More recent approaches relate to the use of 
polymeric micelles, formed by amphilic polymers dispersed in aqueous media [26]. A 
micelle system encapsulates the drug inside its hydrophobic regions allowing the 
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possibility of extended circulation time, favorable bio-distribution and the site-specific 
targeting of the incorporated drug [26]. However, the cytotoxicity of the polymers after 
internalization into cells is a crucial aspect that has raised many concerns. Among the 
most recent DDS are the solid lipid nano-particles (SLN), made-up of a solid lipid matrix, 
which contains surfactants as stabilizers [27]. The advantages of this system are excellent 
physical stability, protection from degradation and controlled drug release. Unfortunately, 
insufficient loading capacity and drug expulsion often occur after polymorphic transition 
during storage. Polymorphic transition is the process of changing from solid crystalline 
phase to any other phase of the same chemical composition at a particular temperature 
and pressure [28]. Polymorphic transition is a reversible reaction. A process called  
“active” or ligand-mediated targeting” was used to increase the site specific actions of 
DDS by interactions with ligands targeted against cell surface molecules [27].  
In order to induce a specific response against a precise defect, new delivery systems with 
all the crucial characteristics should be introduced. For its interesting chemical and 
mechanical properties, carbon nanotubes may find a way to become one of the most 
promising DDS in the near future.  
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Chapter 3  
Applications of Carbon Nanotubes: in Therapeutics 
 
 
CNTs synthesized for pharmaceutical applications need to be procured with utmost care 
as the process should take care of some needed parameters like improved yield, better 
CNT quality and, last but not the least, controlled diameter and chirality. There are 3 
synthesis processes widely used [29]. They are Electric-Arc-Discharge (EAD), Chemical 
Vapor Deposition (CVD) and Laser Ablation (LA), which are selected depending on the 
desired quality, quantity and type of the nanotubes. For example, CNTs synthesized from 
EAD have higher Young’s Modulus and smaller defects in comparison to that of CNTs 
procured by means of CVD [29]. But CVD has other advantages in comparison to EAD 
[29]. CVD can directly synthesize CNTs and deposit CNTs on patterned substrates. 
Unlike EAD, CVD can control nanotube diameter. In spite of the fact that, 
pharmaceutical excipients are mostly inert or non-active components, they are really 
important for formulation. Hence it is necessary to identify the pharmaceutically relevant 
properties of CNTs. CNTs have been used as carrier medicated delivery vehicles for 
biofunctional molecules and as targets for biophysical treatments as well as tissue 
regeneration templates. The inner cavities of CNTs are used as nanochannels for the 
delivery of drugs, proteins and other fluids. Table 1 shows the pertinent physiochemical 
properties of CNTs [29]. 
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Table 1: Pharmaceutically Relevant Properties of CNTs [29].  
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3.1 Functionalized CNTs for Drug Delivery 
 
Carbon nanotubes are popular drug excipients as they have the capability to interact with 
the macromolecules such as proteins and DNAs [30]. A perfect drug delivery system 
should have the capability to perform controlled and targeted drug delivery (Fig 13). 
CNTs have the potential to perform controlled and targeted drug delivery. There are 3 
modes of interaction between CNTs and pharmaceutically active components in drug 
delivery [30]. In the first mode, CNTs act as porous absorbent which entrap active 
components within nanotube mesh. Another mode is to attach compounds functionally to 
the external walls of nanotubes. In the third process, CNTs are used as nanocatheters 
which act as channels to help flow the drug components [30]. 
 
Figure 13: Drug Delivery by means of CNTs. A) CNTs as porous absorbent, B) 
Functional Attachment of Compounds in Nanotube Walls, C) CNT channels Drug 
Component [30].  
In addition, CNTs have been reported as excellent substitutes for other delivery vectors. 
CNTs have the capacity to penetrate through the cell membrane without perturbing their 
morphology. The nanotubes act as nano-needles as they penetrate the cell membrane [31, 
32]. The nature of the penetration does not depend on the functionalized group on the 
nanotube. The nano-needle structure is illustrated in Figure 14 where the FITC 
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(fluorescein isothiocyanate) labeled SWNT derivative was prepared by 1, 3-dipolar 
cycloaddition of azomethine which were highly water soluble [33]. Fluorescence studies 
showed that carbon nanotubes, coupled with azomethine, are able to cross the cell 
membrane and accumulate in the cytoplasm or even sometimes reach the nucleus without 
being toxic to the cell at concentrations up to 10 µM [34]. CNTs enter perpendicularly to 
the cell membrane without disturbing or destroying the membrane itself. Similarly 
SWNTs have been used to deliver streptavidin inside the cell [35]. The adduct (SWNT- 
streptavidin) was known to bind non-specifically with hydrophobic components of the 
cell surface and enter by endocytosis. The SWNTs were first treated with 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride (EDC) and biotin-LC-PEO-amine and 
then dialysis was carried out. To the biotin-functionalized SWNTs fluorescence tagged 
streptavidin molecules were incubated to obtain the adduct [35]. The fluorescence tag 
used was fluorescein isothiocyanate. 
 
 
Figure 14: Covalently attached groups make carbon nanotubes water soluble 
(ammonium) and trackable inside the cells (fluorescein isothiocyanate [33]).  
In the most simplistic approach, the ability of CNTs to penetrate into the walls of cells 
makes them widely usable as drug excipients. Perhaps, covalent or noncovalent bondings 
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of molecules with the external CNT walls play the most important role in molecule 
transfer. For example, CNTs functionalized with amphotericin B (AmB), the most 
effective antibiotic for the treatment of fungal infection, is easily taken by mammalian 
cells with lesser toxicity than by the drug alone [36]. At the highest dose, almost 40% of 
the cells die by the effect of AmB alone, whereas, all the cells remain alive while treating 
with CNTs covalently linked with AmB. Figure 15 and Figure 16 show the easy 
penetration of functionalized CNT into cells and performances of CNT + AmB in 
comparison to AmB alone. Minimum Inhibitory Concentration (MIC) indicates the 
lowest concentration of compound that inhibits visible growth on pathogens [36]. 
 
Figure 15: Molecular Structures of AmB functionalized with CNTs capable of 
penetrating into mammalian cell walls [36].  
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Figure 16: Antifungal activity of AmB conjugated to carbon nanotubes [36].  
3.2 For Protein Delivery 
 
Proteins are found to adsorb on the sidewalls of acid oxidized SWNTs [37]. This is 
advantageous as using this phenomenon; covalent protein-nanotube conjugates can be 
made. Proteins have been found [37] to be transported into various mammalian cells by 
CNTs through endocytosis. Hence, CNTs can be considered as generic intracellular 
transporters for different kinds of proteins. Some important proteins transported by CNTs 
are streptavidin (SA), protein A (SpA), bovine serum albumin (BSA), cytochrome c (cyt-
c) etc [37]. Some mammalian cells getting proteins are HeLa, NIH-3T3 Fibroblast, HL 60 
& Jurkats cell. The entire process starts with fluorescent labeling of proteins. A protein 
solution having concentration of 2 mg/ml is mixed with 50 µL of sodium bicarbonate 
solution (NaHCO3) and then reacted with Alexa-Fluor dye for 1 hour at room 
temperature. The dye-protein conjugate is then passed through a gel separation column, 
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namely Bio-Rad Biogel P30, which purifies the conjugate. In the second step of this 
protein transfer, CNTs are purified, cut and oxidized. The processed protein and 
nanotubes are then mixed and kept at room temperature for 2 hours. Proteins are found to 
adsorb into the walls of CNTs. Atomic Force Microscopy (AFM) is used to test the 
binding of the proteins with nanotube walls and tested with a small sample solution of 
conjugated protein- nanotube on SiO2 piece kept for 30-45 minutes. Results show non-
specific binding of proteins with the nanotube walls. Functional groups provide 
hydrophilicity to nanotubes which make them stable in aqueous solution. As shown in 
Figure 17, the average spacing between protein molecules is found to have a range 
between 20-100 nm [37]. 
 
Figure 17: AFM Images of Various SWNT samples; a) Oxidized Nanotubes Before 
Protein Conjugation; b) Alexa- Fluor 488 BSA; c) Alexa- Fluor 488 SpA; d) Alexa- 
Fluor 488 cyt-c [37]. Scale bar = 100 nm.  
Confocal Microscopic images are also collected to investigate the fate of SWNT- protein 
conjugates. The basic principle of this characterization technique is to check out the 
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fluorescence level in all parts of the conjugated CNTs. Fluorescence level determines the 
adsorption of protein molecules into the CNT walls and is found to originate within the 
cell interior. The fluorescence level of protein solution alone is much lower than that of 
conjugated solution. This indicates that while proteins in solution were not able to move 
across cell membranes properly, CNTs have played the role of efficient cargos 
transporting proteins into mammalian cells [37]. Figure 18 shows the confocal 
microscopy images of increased protein adsorption by cell in a SWNT protein solution 
than protein solution alone. 
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Figure 18: Confocal Microscopy Characterization of Cells; a) HL-60 cells after 
incubation in streptavidin SA-SWNTs; b) HL-60 cells after incubation in BSA-
SWNTs; c) HeLa cells after incubation in SA-SWNTs; d) HeLa cells after incubation 
in cyt-c; e) Cell Cytometry data showing performance improvement of conjugated 
protein solution in comparison to single protein solution [37].  
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Conjugation of pathogen specific antibodies (goat anti E.coli O157) to the SWNTs has 
also been reported [15]. These complexes are functionalized by bovine serum albumin 
(BSA) protein. The SWNT-BSA conjugate was prepared by an amidation (addition of 
amide groups) reaction of the nanotube-bound carboxylic acids with pendant amino 
moieties on BSA. This adduct complex was then able to recognize a pathogen target cell 
in E.coli (O157:H7) through special antigen antibody interactions under normal 
physiological conditions [15]. Nanotubes require covalent functionalization before they 
can actually carry a peptide antigen. Another experiment shows the antigenicity and 
immunogenicity and how the impact of the functionalized nanotubes depends on the 
number of covalent attachments to the nanotubes. Mono and a bis-peptide derivatized 
CNT were designed as shown in Figure 19. 
 
Figure 19: Molecular structures of SWNT functionalized with a peptide derived from 
foot-and-mouth disease virus as a mono (left) and a bis-conjugate (right )[3].  
Analysis was done using Enzyme-linked Immuno-Sorbent Assay (ELISA) test and 
surface plasmon resonance to detect the specific antigen-antibody recognition count and 
concluded that the peptides attached to the nanotubes were well recognized by the 
antibodies (Fig 20). In fact, when a mouse was immunized with the adduct, the peptides 
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produced more antibodies than when free peptides were delivered. A greater response of 
the immobilized antigens was thus confirmed. Moreover, no anti-carbon nanotube 
antibodies in the solution confirmed the fact that the nanotubes themselves had no 
immunogenic properties. The mono-derivatized tubes were able to initiate more response 
than the bis-derivatized nanotubes [3]. 
 
Figure 20: Amino acid and peptide functionalization of carbon nanotubes [3].  
Protein binding to the CNTs is highly selective. Out of numerous proteins in plasma, very 
few bind to carbon nanotubes, which are both as serum as well as plasma proteins. The 
two proteins fibrinogen and apolipoprotein bind to CNTs in greatest quantity [38]. Figure 
21 shows the gel electrophoresis of apolipoproteins conjugated with CNTs in human 
cells. 
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Figure 21: Apolipoprotein conjugated CNTs in human cells, 1: molecular weight 
marker, 2: control experiment (human serum bound to sepharose), 3: human serum 
bound to Double Walled Carbon Nanotube (DWNT) sepharose, 4: human serum 
(1.25µl), 5: control experiment (human plasma bound to sepharose), 6: human plasma 
bound to DWNT sepharose [38].  
3.3 For Gene Delivery 
 
Similar to the previous topics, CNTs functionalized with biological moieties can also be 
used as gene delivery vectors. The main goal of doing gene therapy is to introduce DNA 
efficiently, specifically and safely into the target cell or tissue. Current approaches led to 
rapid disintegration of the nucleic acids [39]. So a delivery system that can mimic the 
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function of a plasmid DNA needs to be developed. Some of the other delivery units for 
DNA are liposomes, cationic lipids and nano particles [39]. Though these approaches 
have yielded some success, the complexity of the binding of the DNA with a CNT helps 
the DNA to remain integrated until it reaches its target organ compared to the other 
models [39]. CNTs and DNA bind primarily by hydrophobic interactions. The DNA 
tends to wind itself around the SWNT to give rise to a hybridized macromolecule. 
Previous studies [39] have shown that a SWNT coated with the plasmid DNA containing 
the β- galactosidase gene resulted in 5- to 10- fold greater expression than when the same 
plasmid was introduced alone in the system. The functionalized nanotubes can also 
condense the DNA-nanotube complex to a limited extent. This compression causes a 
decrease in the surface area of the DNA. So the charge on the DNA accumulates on the 
surface that helps in the increase of the cell membrane interaction due to electrostatic 
forces and increased cellular uptake [39]. 
Gene silencing is considered as one of the emerging fields [30] in genetics which 
basically involves the introduction of short interfering RNA (siRNA). This process 
involves the presence of a messenger. Using complex (-CONH2-(CH2)-NH3+Cl-) as 
messenger, siRNA has been properly attached [30] with CNTs with no loss in 
conformation. The attached moiety can be successfully delivered into cytoplasm CNT 
mediated gene delivery as shown in Figure 22 [30]. 
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Figure 22: Gene Delivery with the help of CNTs via Endocytosis [30].  
Other complexes can also act as messengers. Various non-covalent bonding of bio-active 
molecules with CNTs are illustrated in Table 2.  
Table 2: Non-covalent Binding of Bioactive Molecules to CNTs [30].  
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Further study [40] shows an improvement of the gene silencing technique. In other 
words, improvement of siRNA delivery by SWNTs has been seen. SWNTs are 
functionalized with hexamethylenediamine (HMDA) and polydiallyldimethylammonium 
chloride (PDDA). These complexes translocate in so-called hard to transfect primary 
cells. Released siRNA within the cells provide necessary silencing of target genes. This 
method has certain specific advantages. For example, it has lesser cytotoxic side effects. 
Not only that, PDDA polymer wraps the SWNTs and creates a positively charged surface 
for them and helps to improve their water solubility and provides better binding of siRNA 
to SWNTs [40]. Figure 23 shows that only functionalized SWNTs with PDDA with a 
concentration ratio of 1:1 can bind to siRNA. 
  
 (A)                                                (B) 
Figure 23: Improvement in Si-RNA by Means of PDDA Functionalized SWNTs, (A) 
AFM image of SWNTs functionalized with PDDA (arrows), (B) Gel electrophoresis 
demonstrates the ability of functionalized SWNTs (SWNT:PDDA = 1:1) to bind siRNA 
[40].  
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3.4 Carbon Nanotubes in Cancer Therapy 
 
Recently Dr. Hongjie Dai, and his research group at Stanford University found carbon 
nanotubes can carry the anti-cancer drug doxorubicin [41]. CNTs were reported to carry 
high concentration of the drug and deliver it selectively to cancer cell lines. Experiments 
proved that CNTs can carry almost 4 times its mass of drug through the body system. It is 
hypothesized that the cell lines are permeable, allowing the CNTs to penetrate through 
the cells. As the cancer cell lines swallow the CNTs the loaded doxorubicin causes death 
of the cancer cell lines [41].  
CNTs also help destroy cancerous cells by local heating, which is called hyperthermia. 
High optical absorbance of CNTs and their propensity for endocytosis make them 
suitable candidates for the specific process to destroy cancerous cells. CNTs are 
functionalized with recognizable epitopes, which causes endocytosis of the functionalized 
CNTs by cancerous cells. This is followed by subsequent infrared laser radiation for local 
heating of endocytosed CNTs. Consequently, the cancerous cells are thermally destroyed 
without harming the adjacent healthy cells [30]. Figure 24 shows the use of laser 
radiation and a hyperthermic device to kill a cancer cell. 
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Figure 24: Hyperthermic Cancerous Cell Destruction by CNTs [30].  
CNTs have also been seen to reduce tumor growth in mice cells and shown 
biocompatibility along with little toxicity [42]. A widely used cancer chemotherapy drug 
called paclitaxel (PTX) is branched with polyethylene glycol chains on SWNTs which 
helps in forming a water soluble SWNT-PTX complex via a cleavable ester bond as 
illustrated in Figure 25 [42]. 
35 
 
 
Figure 25: Carbon Nanotube for PTX Delivery [42].  
SWNT-PTX complex shows higher efficiency in suppressing the tumor growth, better 
performance than clinical taxol, superior blood circulation, much better permeability and 
retention. Drug molecules are released from SWNTs into retoculoendothelial system and 
create no toxic effects for the normal organs as shown in Figure 26 [42]. 
 
Figure 26: SWNT-PTX Complex Reduces Tumor Growth [42]. 
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A new way to deliver platinum anticancer pro drug with a lethal dose was recently 
discovered [43]. The acidic environment in the tumor cells causes the release of the pro 
drug cisplatin to the target organs. Ability of platinum (IV) complexes to resist ligand 
substitution enables SWNTs to act as a “longboat”[43] to pierce through the cells and 
deliver a lethal dose of cisplatin. This is the first time that CNTs were used to carry drugs 
rather than encapsulate the drugs [43].  
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Chapter 4 
 
Toxicity Studies 
 
One of the major issues in biological systems is the level of toxicity involved in any new 
models. Substances that are not toxic in the environment often have some adverse effects 
when administered inside the body. Another major issue for any biological model is, 
when any external substance is introduced inside a body, it needs to be disintegrated once 
their job is done. So this raises the issue regarding the biocompatibility of the substance. 
With respect to carbon nanotubes, the level of toxicity depends mainly on its manufacture 
[44]. Though highly purified nanotubes are being used, any remaining traces of metals 
like iron and nickel could cause damage to the systems. Though it is such an important 
issue, not many studies have been done on analyzing the cytotoxic effect of nanotubes. In 
the last decade, Adelmann et al. (1994) reported that fullerenes are toxic on alveolar 
macrophages. Even more recently, studies have shown that cytotoxicity of water soluble 
fullerene derivatives is a function of the degree of surface modification [41]. So, if carbon 
nanotubes are considered as a derivative of the fullerenes along one axis, then they 
should also have some toxic effects. Other experiments in rats have shown that carbon 
black particles might produce a significant lung toxicity that potentially increases by 
decreasing the particle size and by increasing the surface area.     
Administration of any potential therapeutic agent involves crossing several layers from 
tissue endothelium into the interstitial space of tissues, through the cell membrane into 
the intracellular compartments. The therapeutic agent finally has to find its way through 
the perinuclear membrane into the nucleus of the cell [45]. Figure 27 shows all the 
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different layers a drug has to penetrate to enter the nucleus of the cell. The different 
cellular layers have a significant role to play during drug administration. Development of 
a potent drug delivery system should consider all the above mentioned parameters for the 
in-vivo fate of any administered material.  
  
 
Figure 27: In Vivo Barriers and Critical Parameters affecting the fate of 
nanomedicines [45].  
Carbon nanotubes consist of some amazing physiochemical properties which make them 
suitable candidates for nanomedicines. They have ordered structure with high aspect ratio 
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associated with very light weight. Superior mechanical strength of CNTs has already 
been discussed. This is followed by their high thermal and electrical conductivity, 
metallic or semi-metallic behavior and high surface area. These properties make CNTs 
perfect materials for biomedical applications. In general, studies show that nanoparticles 
have harmful effects because of their high surface area and toxicity on the surface [45]. 
SWNTs can become non-toxic by functionalizing them with phenyl-SO3H or phenyl-
carboxyl groups [45]. Figure 28 represents different important properties of CNTs useful 
for pharmacological and toxic applications. 
 
Figure 28: CNT properties determining pharmacological and toxicity profile [45].  
 
40 
 
Several studies have been done to address the growing concern on the toxicity of CNTs 
in human bodies. Table 3 shows a snapshot of a review of the various toxicological 
studies and results. 
 
Table 3: Invivo studies performed with CNT [45].  
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Chapter 5 
Simulation Models 
 
Even though a number of experimental studies have been done to explore the application 
of carbon nanotubes in the field of biology and medicine, this field of study is still in the 
early stage of development. Research studies are made more varied and less redundant. 
Recently, scientists have tried to analyze this problem from a computational point of 
view. In 2005, a few computational analyses were done on the binding free energies 
between peptides and single-walled nanotubes [46]. The simulation process involved the 
different types of interaction between the peptides and the SWNTs using molecular 
dynamics (Amber 7) methods and a continuum solvation model. The binding free 
energies are then estimated based on the thermodynamics theories. The binding free 
energies consider both the solute and the solvent interactions. The energy contributions 
show that the bonds are mostly the non-covalent bonds in which van der Waals 
interactions play the most significant roles. Aromatic rings on peptides have strong 
affinities for the CNT surface. The estimated results of the binding free energies from the 
model were compared with experimental results. Some insight was also given on the 
conformations of the binding peptides from the model which would not be possible for us 
to know from just doing the experiments. 
Other simulation studies have been also carried out on protein fragment models. 
Trzaskowski et al. [47] explored dynamic properties of two protein fragments’ interaction 
with single walled carbon nanotubes. This model included all 3 kinds of interactions 
between peptides and SWNT: outer wall interaction, proteins encapsulated into 
nanotubes interaction and covalent interactions. Two basic structured protein fragments 
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were designed for this model: a beta hair pin model and alpha helix model. These are the 
two basic structured protein molecules found in most of the biomacromolecules. The beta 
hairpin model was designed from chignolin (10 amino acid peptide). The alpha beta helix 
model was derived from the de-novo designed peptide used in computational study of 
prion propagation. The SWNTs were built relatively short (~22 Å). Two types of CNTs 
were designed: (22,0) nanotube with a diameter of 17 Å and (30,0) nanotube with a 
diameter of 23.5 Å. The software package that was used to simulate all the molecular 
dynamics was CHARMM27. The aspartate and glutamate residues were deprotonated 
and the lysine residues were protonated. The simulation model was a two step process: 
first the peptide-nanotube complex was immersed into TIP3P water molecules and 
counter ions were added if required. The model was run for 24000 steps. Figure 29 
shows the schematic representation of the simulation model.  
 
Figure 29. Schematic representation of the (a) beta-hairpin peptide encapsulated into 
(22,0) nanotube and (b) the covalent linker used in the study [47].  
Results show that encapsulation of peptides within nanotubes has almost no effect on the 
dynamic properties of the peptides, i.e., encapsulation does not have much effect on the 
secondary structures of the proteins. Therefore, the conclusion was reached that proteins 
tend to stay in their native conformation during encapsulation. Outer wall interaction 
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studies show that both the peptides bound with almost similar root mean square deviation 
(rmsd) values if not identical. On the other hand, covalent linkages attached to CNTs 
interact very differently with the peptides. The model shows that, when CNTs were 
functionalized with -COOH groups, the peptides that bind to the inner wall of the 
nanotubes undergo huge conformational changes for both the structures and acquire a 
totally different conformation that is very stable. This conformational change may be due 
to the constraints put on the peptides upon linkage together with the SWNTs. Figure 30 
shows the comparative study results of the root mean square deviation (rmsd) values of 
the peptides with respect to their structures and binding location.  
   
Figure 30. Comparison between the rmsd values for alpha-helix and beta-hairpin 
models linked covanlently to (22,0) nanotube [47].  
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Chapter 6 
 
Docking of Vasopressin with Functionalized Single Walled 
Carbon Nanotubes 
 
A docking study was performed using functionalized single walled carbon nanotubes and 
model peptide, vasopressin. The binding free energy of the interaction was calculated to 
assess the feasibility of the SWNT-vasopressin model. The long-term objective of the 
project to which this research contributes is to assess the feasibility of single walled 
carbon nanotubes as a potential drug delivery system for proteins and peptides. 
6.1 Background Study of Vasopressin 
 
Vasopressin is a peptide hormone. Some of its aliases are Argipressin and Anti Diuretic 
Hormone (ADH). It is synthesized from preprohormone precursor in the hypothalamus. 
After synthesis, it is stored in the vesicles of posterior pituitary [48]. A broad overview of 
the arrangement of the amino acids is shown in Figure 31. This structure of vasopressin 
is drawn using the Swiss–PDB Viewer Deep View (SPDBV) visualization tool with 
vasopressin PDB structure. 
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Figure 31: Molecular structure of Vasopressin, plotted using DeepView viewer 4.0 
(http://spdbv.vital-it.ch/) [49] 
 
6.1.1 Structure of Vasopressin  
 
Vasopressin is a 9-residue polypeptide with a sequence C-Y-F-Q-N-C-P-R-G-NH2 [50]. 
The cysteine residues at position 1 and 6 form a disulfide bond. The Asn5-I to Gly9-I of 
vasopressin constitutes the reactive site loop. Arg8-I is the reactive site residue located at 
the C terminus and other residues, forming a cyclic ring, lying at the entrance of the 
trypsin active site. The vasopressin molecule has uniform electron density and the 
disulphide bond confers stability to the molecule (Fig 32). There is also an intramolecular 
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hydrogen bond between Tyr2-I and Gln4-I and another between Gln4-I and Cys6-I. 
These hydrogen bonds provide stability to the cyclic part of the peptide. There are also a 
few hydrogen bonds along the C-terminal of the molecule.  
 
 
 
 
Figure 32: Stereo view of the electron density map (2Fo-Fc) at the 1  level plotted using 
PYMOL (http://pymol.sourceforge.net/) for vasopressin. The intramolecular hydrogen 
bonds are shown as dotted lines [50].  
6.1.2 Therapeutic Applications of Vasopressin/Arginine vasopressin 
(AVP) 
 
The primary physiological function of vasopressin is to maintain fluid balance in the 
body in response to any environmental stimuli or changes [51]. Recent studies [51] show 
that vasopressin also tends to play a very important role in adult cardiac arrests as well as 
adult and pediatric vasodilatory shock. Various randomized clinical trials were performed 
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for years to validate the role of vasopressin in cardiac arrests. The largest randomized 
double-blinded study of AVP versus epinephrine was conducted in 2004 that enrolled 
1186 patients [52]. Patients were randomized to receive up to two doses of 1.0 mg doses 
of epinephrine or two 40 IU doses of AVP at the discretion of the physician. 589 patients 
received AVP and 597 patients received epinephrine. Table 4 shows that the use of 
vasopressin improves the rates of survival to hospital admission (and discharge) better 
than epinephrine in adults. The American Heart Association (AHA) and European 
Resuscitation Council (ERC) now recommend use of vasopressin in adults. Use of 
vasopressin has shown no significant influence on pediatric resuscitation patients. 
Vasopressin infusion for vasodilatory shock is gaining importance. Most recent studies 
have shown that AVP acts in situations of vasodilatory shock where most of the pressors 
fail to act. AVP also demonstrates increased systemic vascular resistance [51].  
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Table 4: Primary and subgroup analyses of 1186 patients in study. 
 
Group/subgroup, outcome Vasopressin, 
no. (and %) 
Epinephrine, 
no. (and %) 
Odds ratio 
(95% CI) p value 
All patients 
ROSC 145/589 (24.6) 167/597 (28.0) 1.2 (0.9-1.5) 0.19 
Hospital admit 214/589 (36.3) 186/597 (31.2) 0.8 (0.6-1.0) 0.06 
Hospital discharge 57/578 (9.9) 58/588 (9.9) 1.0 (0.7-1.5) 0.99 
Ventricular fibrillation 
ROSC 82/223 (36.8) 106/249 (42.6) 1.3 (0.9-1.8) 0.20 
Hospital admit 103/223 (46.2) 107/249 (43.0) 0.9 (0.6-1.3) 0.48 
Hospital discharge 39/219 (17.8) 47/245 (19.2) 1.1 (0.7-1.8) 0.70 
Pulseless electrical activity 
ROSC 21/104 (20.2) 17/82 (20.7) 1.0 (0.5-2.1) 0.93 
Hospital admit 35/104 (33.7) 25/82 (30.5) 0.8 (0.5-1.6) 0.65 
Hospital discharge 6/102 (5.9) 7/81 (8.6) 1.4 (0.5-4.7) 0.47 
Asystole 
ROSC 42/262 (16.0) 44/266 (16.5) 1.0 (0.7-1.6) 0.87 
Hospital admit 76/262 (29.0) 54/266 (20.3) 0.6 (0.4-0.9) 0.02 
Hospital discharge 12/257 (4.7) 4/262 (1.5) 0.3 (0.1-1.0) 0.04 
CI = confidence interval; ROSC = restoration of spontaneous circulation 
Adapted with permission from Table 3, Wenzel V, et al. <17> © 2004 Massachusetts Medical 
Society. Odds ratio measures the strength of association between two binary data values. p value is 
the probability of obtaining a result against the null hypothesis.  
 
Arginine vasopressin is also termed as a “promising rescue drug” in the treatment of 
uncontrolled hemorrhagic shock [53]. Hemorrhagic shock occurs due to excessive blood 
loss from the body. Figure 33 shows the pathophysiological path of hemorrhagic shock. 
 
49 
 
 
 
Figure 33. Pathophysiologic cascade of hemorrhagic shock [53].  
There are mainly two types of hemorrhagic shock. Controlled shock occurs when the 
amount of blood loss does not outrange the neuro-endocrine stress response and the loss 
can be controlled before the heart collapses. Uncontrolled hemorrhage occurs when the 
blood loss cannot be controlled at the site and the catecholamines are insufficient to 
stabilize cardiovascular functions. Infusion of fluid alone sometimes cannot resuscitate 
uncontrolled hemorrhage. It may lead to extensive blood clotting and hence could be 
detrimental. The crystalloid and colloid solutions sometimes cause dilutional 
coagulopathy which leads to dilution of clotting factors that may impair cellular 
50 
 
homeostasis. Infusion of blood may also result in increased blood pressure at the site of 
blood loss. All these consequences suggest that fluid infusion alone cannot rescue 
uncontrolled hemorrhage. Vasopressin, on the other hand, increases the neuro-endocrine 
stress response. Due to uniform distribution of vasopressinergic receptors, it significantly 
increases vasoconstriction in the vascular beds other than coronary, pulmonary and 
cerebral circulation. This can reduce blood loss and maintain homeostasis. Sometimes, 
when uncontrolled hemorrhage is followed by brain death, AVP can reduce secondary 
neurological damage due to ongoing hypotension and cerebral hypo perfusion. In 2000, 
Voelckel and colleagues studied the effect of AVP on 7 pigs [53]. The AVP effects were 
compared with a group of 7 pigs who were treated with epinephrine and a group of 7 pigs 
who were treated with placebo saline water. Uncontrolled hemorrhage was induced by an 
incision across the right medial liver lobe. Figure 34 shows the summary of the 
comparative effect of AVP vs. epinephrine vs. placebo saline. 
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Figure 34: Mean ± SEM for heart rate, mean arterial pressure, and total blood loss 
before, during, and after administration of a 0.4 units/kg bolus dose, 0.04 units/kg/min 
continuous infusion of vasopressin (squares; n=7) vs. a 45 µg/kg bolus dose, and 5 
µg/kg/min continuous infusion of epinephrine (diamonds; n=7) vs. equal volumes of 
saline placebo (circles; n=7). Uncontrolled hemorrhage, the no-treatment interval after 
liver injury; experimental therapy, attempt of haemodynamic stabilization with either 
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vasopressin, epinephrine, or saline placebo; liver tamponade, manual compression of 
the liver injury to control bleeding; BL, measurements at baseline before induction of 
hemorrhagic shock; DA, administration of study drugs or placebo; arrow, second bolus 
dose of epinephrine; *p <0.004 for epinephrine and vasopressin vs. saline placebo; p < 
0.002 for vasopressin vs. epinephrine and saline placebo; p<0.0001 for vasopressin 
vs. epinephrine and saline placebo. No statistical comparison was performed after 
minute 10 during vasopressor therapy because of the death of all animals that received 
epinephrine and saline placebo, respectively [53].  
6.1.3 Drug delivery systems of Arginine Vasopressin  
 
Several methods have been used to incorporate vasopressin inside the human body [54, 
55]. Two distinct methods are use of peptide drug delivery systems [54] and 
iontophoretic methods [55]. In 1999, Aoyagi et al. [54] tried to fabricate peptide delivery 
systems using arginine vasopressin as the model drug. AVP was incorporated using 
dialysis method. The polymer delivery system used constituted of poly(polyethylene-
glycol)-poly(L-aspartic acid) [PEG-P(Asp)] block copolymer. The polymer system 
formed nano associates from PEG-P (Asp). AVP molecules were incorporated into the 
nano-associates, which were then measured by IR light spectra [Fig 35].  
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Figure 35. IR spectra of PEG-P (asp) associates incorporated (a) without AVP and (b) 
with AVP (run No.1 in Table 5 ) [54] .  
Table 5 shows a summary for loading of AVP in acid type PEG-P (Asp) polymer and 
mixture of acid and salt PEG-P (asp) polymer.  
Table 5. Incorporation of AVP into PEG-P (Asp) nano-associates [54]. .  
 
 
 
Ionotophoretic delivery of a peptide is the propulsion of a highly charged species (peptide 
molecules) transdermally by generating electrical force fields in the solution. Electrical 
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parameters and current densities are known to influence the passage of an actively 
charged species in the solutions [55]. In-vitro studies were conducted by Nair et al.  [55] 
using rat skin. Skin hydration plays a very important role in the amount of peptide 
permeated per unit skin area. 
 
6.2. Docking Tool   
 
Docking Server   
Source: http://www.dockingserver.com/web/ 
All the docking parameters were calculated using Docking Server [56]. Docking Server is 
developed and maintained by Virtua Drug Ltd and is a free web service that calculates 
the best geometry of ligand protein interactions.  
CoNTub   
Source: http://www.ugr.es/~gmdm/contub.htm  
CoNTub [57] is freeware that generates PDB structures of nanotubes which were 
developed in 2004 by Melchor et.al. [57]. CoNTub is a computer program solely 
dedicated to generate complex geometrical structures of carbon nanotubes (SWNT and 
MWNT) for docking purposes. This tool was first designed to determine the coordinates 
of heterojunctions between two unknown nanotubes. Later it added more features for 
generating Protein Data Bank (PDB) structures of complex carbon nanotubes. For the 
purpose of this docking research, several single walled carbon nanotube structures with 
various dimensions were obtained in the PDB format. 
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6.3 Method  
 
Vasopressin was used as a model peptide due to its extensive and critical clinical 
applications. It is a fairly small peptide which constitutes the following 9 amino acids: C-
Y-F-Q-N-C-P-R-G-NH2. The native structure of the protein was downloaded from 
Protein data bank as a PDB file. The PDB ID 1yf4 contains the structure of Lysine-
Vasopressin. For the purpose of docking, to concentrate only on vasopressin, only the 
chain B of 1yf4 was selected from the docking parameters. The protein parameters were 
optimized by calculating the electrostatic properties of vasopressin and defining the 
active site of vasopressin. Next, the vasopressin molecule was put into solution (H2O) for 
the calculation of solvation energies.  
The docking server supports only specific formats for ligands. The PDB file format for 
single walled carbon nanotubes was obtained from the tool CoNTub. In order to check 
whether the diameter and the functionalized atoms of the nanotube makes any difference 
in the overall interaction of the peptides and SWNTs, 3 sets of SWNTs with 4 different 
(n,m) values were created:  
a) Non-functionalized SWNTs 
• (5,0) nanotubes with 10 Å length 
• (5,5) nanotubes with 10 Å length 
• (10,0) nanotubes with 10 Å length 
• (10,10) nanotubes with 10 Å length 
 
b) Functionalized SWNTs with Nitrogen atoms 
• (5,0) nanotubes with 10 Å length 
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• (5,5) nanotubes with 10 Å length 
• (10,0) nanotubes with 10 Å length 
• (10,10) nanotubes with 10 Å length 
c) Functionalized SWNTs with Hydrogen atoms  
•  (5,0) nanotubes with 10 Å length 
• (5,5) nanotubes with 10 Å length 
• (10,0) nanotubes with 10 Å length 
• (10,10) nanotubes with 10 Å length 
Nitrogen and hydrogen atoms were attached to each of the terminal carbon atoms at 
either end of the respective SWNTs e.g. a (5,5) H-functionalized SWNT and (5,5) N-
functionalized SWNT would have (5+5)=10 hydrogen and 10 nitrogen atoms attached 
respectively. Each type of SWNT was made to interact with only 1 molecule of 
vasopressin. The 3-dimensional ligand structures were optimized for docking using the 
following parameters: optimized geometry, identification of rotational bonds and 
calculation of semi-empirical charges in pH=7.0.  
Finally, the ligands were plunged into the peptide made to solution and the docking study 
was done on 100 runs using a scoring function to determine the intermolecular energies 
between the molecules. Docking server uses the scoring function from AutoDock4 [58, 
59]. Each docking result was obtained from 100 runs that terminated after a maximum of 
250,000 energy evaluations. The population size was 150. The docking search used a 
translational step of 0.2 Å, and quaternion and torsion steps of 5.  
Advance settings  
Figure 36. shows a snapshot of the advance settings for a docking step.  
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Figure 36. Snapshot of the advance settings for a docking experiment 
 
The first three fields [56] are for making changes to the state variables that affect 
Lamarckian Genetic Algorithm (LGA). 
“tstep” stands for Translational step. The default value is 0.2 Å 
“qstep” is definied as quarternion step / rigid body orientation. Unit quarternion is a 
mathematical notation to denote orientation and rotations of objects in 3 dimensional 
spaces. The default value is 5° 
“dstep” is defined as the torsion step/dihedral angle. It means dstep measures the 
sharpness of a twist movement for each dihedral angle (angle between two vector planes). 
The default value is 5° 
 “rmstol” denotes the root mean square deviation tolerance. The default value is 2.0 
“ga_pop_size” denotes the number of individuals in a population. Each individual is a 
coupling of a genotype and its associated phenotype. Usually, this number is fixed 
throughout the run. Typical values range from 50 to 200. The default value is 150. 
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“ga_num_evals”  and “ga_num_generations” set the limits to the docking run. The 
docking run generates ga_num_evals  number of energy evaluations for each  generation 
denoted by ga_num_generations. The default values are 
 ga_num_evals : 250,000  
ga_num_generation : 540,000  
“ga_run” denotes the number of times the docking experiment should be run. The 
default value is 100.  
6.4 Results 
 
Table 6 shows the summary results from the docking experiments between non-
functionalized, nitrogen functionalized and hydrogen functionalized SWNTs with 
vasopressin.    
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Table 6: Comparative Binding Free Energy values of Non-Functionalized, N-
Functionalized and H-Functionalized SWNTs with vasopressin 
SWNTs 
Dimen 
sion 
(n,m) 
Length
(10 
Å) 
Estimat
ed 
Binding 
Free 
Energy 
(kcal/m
ol) 
Gallery Results 
Non 
Function
alized 
(5,0) -5.04 
(5,5) -4.78 
(10,0) -5.22 
(10,1
0) 
+1.5e+
0.3 
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Nitrogen-
Function
alized 
(5,0) -3.38 
(5,5) -10.43 
(10,0) -3.36 
(10,1
0) 
+11.10 
Hydroge
n-
Function
alized 
(5,0) -5.07 
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(5,5) -8.14 
(10,0) -7.58 
(10,1
0) 
+52.25 
 
The detailed results for docking of all the structures are available in Appendix A.  
6.5 Discussion 
 
The scoring functions used to calculate the intermolecular energies and the solvation 
energies are obtained from AutoDock4 [58, 59] which uses the LGA and the Solis & 
Wets Local search method [60]. This algorithm helps to minimize the intermolecular 
energies by random search method. LGA method is very useful in complex problems like 
docking where the function had a lot of local minima points and computer memory 
available is less. Each ligand is orientated randomly in the initial position having an 
unknown random torsional energy. This randomized orientation helps to make the model 
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free from bias. Each simulation is run for 100 times that terminates after a maximum of 
250,000 energy evaluations. 100 runs help us to make the probability of occurrence of an 
orientation more specific.  
Docking of vasopressin with various structurally different SWNTs helps evaluate the 
probable factors that influences the binding free energy calculations. The lower the Gibbs 
Free Energy (binding free energy) the more stable is the interaction. Our docking 
experiments tried to focus mainly on 2 factors:  
a) The diameter of a SWNT, and 
b) Functionalization of SWNTs. 
a) The diameter of a SWNT: For bigger diameters, the model peptide tends to bind 
to the inner walls of the tube creating really unstable bonds. From the above 
results, peptides that bind to the outer walls of the tubes tend to form stronger 
bonds, i.e., less binding free energy values. The peptides that tend to bind to the 
inner walls of the bigger diameter tubes create higher energy bonds hence making 
the whole system unstable. Therefore, the smaller the diameter of the tube, the 
better the interactions. 
b) The functionalization of SWNTs: 3 sets of docking experiments were carried out, 
non-functional, SWNTs functionalized with hydrogen and SWNTs functionalized 
with nitrogen. The results show that functionalized carbon nanotubes tend to form 
stronger bonds with the peptides. In addition, the functionalized nanotubes tended 
to intake more peptides molecules (from the percentage frequency of the results 
page) compared to the non-functionalized. From the energy values and the 
number of bonds formation of the H-functionalized and N-functionalized SWNTs 
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with vasopressin residues, we can see that the N-functionalized SWNTs have 
more stable interactions with vasopressin than H-functionalized SWNTs. It should 
also be noted that same number of hydrogen atoms were loaded to each SWNT as 
the number of nitrogen atoms. Nitrogen atom has an un-pair electron which tends 
to bind better with vasopressin residues. N-functionalized SWNTs form more 
number of stable bonds like hydrogen bonds, polar bonds, hydrophobic bonds and 
cation-pi bonds (Appendix A).  
  
Conclusion 
 
The interaction of peptides with carbon nanotubes appears to be a very promising field 
for future study. Functionalization of the nanotubes may assist in their use as potential 
vectors for drug delivery. Docking studies done in this project do show that 
functionalized single walled carbon nanotubes have a high tendency to interact with 
peptides in a stable manner. It also shows that N-functionalized SWNTs form more 
number of bonds with vasopressin than H-functionalized SWNTs. Smaller diameters in 
SWNTs favor outer-wall interactions which is more stable than inner wall interactions. 
An extension to this docking study would be to explore energy values for increased or 
decreased length of SWNTs. A possible validation of the energy values obtained from the 
above docking studies could be done by interacting vasopressin with functionalized 
SWNTs in wet lab. 
However, the docking experiments can only create hypothetical scenarios. Biological 
systems are one of the most complex systems that have ever been studied and hence it is 
very difficult to gauge every aspect of a biological system into a simulation model. But 
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docking studies can certainly give a head-start to what we might expect in the real life 
situation.  
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